November 20, 2025

New Publication: Hi-STEMProteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDACNew Publication: Hi-STEM

New Publication: Hi-STEMProteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDACNew Publication: Hi-STEM

Abstract

Objectives: 

To investigate the proteomic profile of different molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) and understand their impact on patient outcomes, particularly focusing on pathways involved in xenobiotic metabolism and drug resistance.

Methods: 

The study utilized the serum-free PACO cell culture model and a quantitative prefractionation-based MALDI/MS approach to establish the proteomic profiles of various PDAC subtypes. Differential protein regulation was analyzed to identify systematic alterations in metabolic and drug resistance pathways. Mechanistic studies involved the knockdown and overexpression of key proteins to assess their role in drug resistance.

Results: 

Proteomic analysis revealed subtype-specific alterations, particularly in pathways associated with xenobiotic metabolism and drug resistance. Notably, CYP2S1, a member of the CYP450 family, was upregulated in the HNF1A+ PDAC subtype. CYP2S1 levels were further inducible by polyaromatic hydrocarbons (PAHs) and SN38, the active metabolite of irinotecan via AHR. Mechanistic studies demonstrated that knockdown of AHR or CYP2S1 sensitized PDAC cells to SN38, whereas overexpression of CYP2S1 increased resistance to SN38.

Conclusions: 

The findings highlight the significant role of CYP2S1 in mediating drug resistance in certain PDAC subtypes. Targeting CYP2S1 and its regulatory pathways could enhance the efficacy of chemotherapeutic agents like irinotecan in treating PDAC. These results provide new insights into the molecular mechanisms underlying PDAC subtype-specific drug resistance and suggest potential therapeutic targets.


Thiel, Vera PhD,†; Nadler, Wiebke M. PhD,†; Kerner, Alexander PhD,†; Kuhlmann, Laura PhD,†,‡; Reitberger, Manuel PhD,†; Vorberg, Tim,†; Schwerd-Kleine, Paul,†; Noll, Elisa PhD; Giese, Nathalia A. MD; Yen, Hsi-Yu Dr. med. vet.§,∥,¶; Steiger, Katja Dr. med. vet.§; Vogel, Vanessa,†,#; Klein, Corinna,†; Hackert, Thilo MD*; Koschny, Ronald MD††; Opitz, Christiane A. PhD; Trumpp, Andreas PhD,†; Sprick, Martin R. PhD,†; Rösli, Christoph PhD*,†. Proteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDAC. Pancreas ():10.1097/MPA.0000000000002553, August 29, 2025. | DOI: 10.1097/MPA.0000000000002553

Our latest News

discover more
China’s NMPA approves Promega’s MSI detection kit as a companion diagnostic for KEYTRUDA®

China’s NMPA approves Promega’s MSI detection kit as a companion diagnostic for KEYTRUDA®

The National Medical Products Administration (NMPA) in China has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic device in China. It is intended as a companion diagnostic to identify patients with MSI-high (MSI-H) solid tumors for treatment with KEYTRUDA® (pembrolizumab), the anti-PD-1 therapy from Merck & Co., Inc., […]

aimed analytics GmbH highlighted in deutsche-startups.de

aimed analytics GmbH highlighted in deutsche-startups.de

5 neue Startups: ONOX, aimed analytics, Recarbox, FORMIC, showroom.fm Es ist wieder soweit – neue Startups stehen in den Startlöchern! Hier sind einige spannende junge Unternehmen, die man kennen sollte. Heute werfen wir einen Blick auf diese Neugründungen: ONOX, aimed analytics, Recarbox, FORMIC und showroom.fm. deutsche-startups.de stellt heute erneut eine Auswahl junger Startups vor, die […]

BioMed X Launches First Research Project in Partnership with the Government of Barbados to Advance Therapy of Early Diabetic Kidney Disease

BioMed X Launches First Research Project in Partnership with the Government of Barbados to Advance Therapy of Early Diabetic Kidney Disease

Bridgetown, Barbados, January 27, 2026 – BioMed X, a leading innovation hub for pharma, today announced the launch of its first research project in partnership with the Government of Barbados and with support from the European Union’s PharmaNext Programme. The new global call for research proposals, entitled “AI-Enabled Therapy of Early Diabetic Kidney Disease in Barbados,” addresses one of the most pressing and underexplored […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp